Tokyo Tape
Sign in
← Vital Ksk Holdings

Quarterly report · Q2

3151.TEDINET S100S8PO
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥294.2bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥581.3bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥290.2bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥2.9bn2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥1.5bn2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥3.5bn2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥6.0bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥2.4bn2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥3.5bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥2.4bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥2.3bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.8bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.4bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥2.4bn2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥1.5bn2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥321.7bnat 2023-09-30Cons.Assets
Total assets¥297.3bnat 2023-03-31Cons.Assets
Total assets¥316.4bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥219.0bnat 2023-09-30Cons.Liabilities
Total liabilities¥197.2bnat 2023-03-31Cons.Liabilities
Net assets / equity¥102.8bnat 2023-09-30Cons.Net assets
Net assets / equity¥100.2bnat 2023-03-31Cons.Net assets
Net assets / equity¥103.6bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥30.5bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥19.0bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥26.9bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥15.1bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥23.5bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥23.2bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥16.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥3.0bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥4.0bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥1.5bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥1.0bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.2bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥3.4bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥4.1bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥2.6bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥45.782023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥28.032023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥92.692022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥27.422022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥15.42022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio31.6%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio33.3%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio32.4%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-09-30¥3.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-09-30¥2.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-09-30¥1.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-09-30−¥108m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥6.6bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥6.6bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30¥39m
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentrevenue2023-04-01 → 2023-09-30¥282.5bn
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentrevenue external2023-04-01 → 2023-09-30¥277.2bn
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥5.3bn
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentsegment profit2023-04-01 → 2023-09-30¥2.6bn
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥9.4bn
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥9.4bn
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥6m
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥114m
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥5.6bn
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥5.6bn
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥0
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥183m
—segment totalrevenue2023-04-01 → 2023-09-30¥297.5bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥292.2bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥5.3bn
—segment totalsegment profit2023-04-01 → 2023-09-30¥2.9bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥300.8bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥294.2bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥6.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥2.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-09-30¥3.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-09-30¥2.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-09-30¥1.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-09-30−¥146m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥6.4bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥6.4bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30¥58m
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentrevenue2022-04-01 → 2022-09-30¥279.0bn
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentrevenue external2022-04-01 → 2022-09-30¥273.8bn
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥5.1bn
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentsegment profit2022-04-01 → 2022-09-30¥1.4bn
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥9.0bn
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥9.0bn
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3m
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥32m
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥5.3bn
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥5.3bn
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥0
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥182m
—segment totalrevenue2022-04-01 → 2022-09-30¥293.3bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥288.2bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥5.1bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥1.6bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥296.6bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥290.2bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥6.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥1.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 545
ItemContextValueUnit
Rent expenses noePrior1YTDDuration41000000JPY
Rent expenses noeCurrentYTDDuration39000000JPY
Other noePrior1YTDDuration9000000JPY
Other noeCurrentYTDDuration18000000JPY
Non operating expensesPrior1YTDDuration102000000JPY
Non operating expensesCurrentYTDDuration108000000JPY
Ordinary incomePrior1YTDDuration2423000000JPY
Ordinary incomeCurrentYTDDuration3478000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration13000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration33000000JPY
Gain on sales of investment securities eiPrior1YTDDuration59000000JPY
Gain on sales of investment securities eiCurrentYTDDuration169000000JPY
Other eiPrior1YTDDuration－JPY
Other eiCurrentYTDDuration24000000JPY
Extraordinary incomePrior1YTDDuration72000000JPY
Extraordinary incomeCurrentYTDDuration227000000JPY
Loss on sales of noncurrent assets elPrior1YTDDuration0JPY
Loss on sales of noncurrent assets elCurrentYTDDuration－JPY
Impairment loss elPrior1YTDDuration22000000JPY
Impairment loss elCurrentYTDDuration49000000JPY
Loss on valuation of investment securities elPrior1YTDDuration55000000JPY
Loss on valuation of investment securities elCurrentYTDDuration42000000JPY
Soil removal expenses elPrior1YTDDuration62000000JPY
Soil removal expenses elCurrentYTDDuration－JPY
Dismantlement expense elPrior1YTDDuration－JPY
Dismantlement expense elCurrentYTDDuration47000000JPY
Other elPrior1YTDDuration5000000JPY
Other elCurrentYTDDuration29000000JPY
Extraordinary lossPrior1YTDDuration145000000JPY
Extraordinary lossCurrentYTDDuration169000000JPY
Income before income taxesPrior1YTDDuration2350000000JPY
Income before income taxesCurrentYTDDuration3536000000JPY
Income taxesPrior1YTDDuration862000000JPY
Income taxesCurrentYTDDuration1139000000JPY
Profit lossPrior1YTDDuration1487000000JPY
Profit lossCurrentYTDDuration2397000000JPY
Profit loss attributable to non controlling interestsPrior1YTDDuration49000000JPY
Profit loss attributable to non controlling interestsCurrentYTDDuration50000000JPY
Profit loss attributable to owners of parentPrior1YTDDuration1437000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration2347000000JPY
Profit lossPrior1YTDDuration1487000000JPY
Profit lossCurrentYTDDuration2397000000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration3806000000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration2322000000JPY
Remeasurements of defined benefit plans net of tax ociPrior1YTDDuration-178000000JPY
Remeasurements of defined benefit plans net of tax ociCurrentYTDDuration-182000000JPY
Share of other comprehensive income of associates accounted for using equity method ociPrior1YTDDuration213000000JPY
Share of other comprehensive income of associates accounted for using equity method ociCurrentYTDDuration413000000JPY
Other comprehensive incomePrior1YTDDuration3841000000JPY
Other comprehensive incomeCurrentYTDDuration2553000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass